# A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

> **NCT05061147** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Maxinovel Pty., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia
- Acute Myeloid Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** MAX-40279-01

## Key facts

- **NCT ID:** NCT05061147
- **Lead sponsor:** Maxinovel Pty., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-16
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061147, "A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05061147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*